Cipla and Kemwell Biopharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the execution of a joint venture agreement to develop, manufacture and commercialize biosimilars for global markets. For this purpose, a joint venture company shall be incorporated to enter the respiratory biosimilars space.
Cipla and Kemwell to launch biopharmaceutical products
Under the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing, and commercialization of biopharmaceutical products. Cipla’s respiratory prowess combined with Kemwell’s expertise in biologics will accelerate bringing these essential products to market.
Umang Vohra, managing director & global chief executive officer of Cipla, said: “This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership. Guided by our purpose of ‘Caring for life,’ our partnership with Kemwell will help serve unmet needs of patients across the globe.”
Anurag Bagaria, chairman and chief executive officer of Kemwell, said: “We are very excited about combining the strengths of Cipla’s expertise in the development and commercialization of respiratory products and Kemwell’s biologics capabilities. Through this joint venture, we aim to make cost-effective biotherapeutics available to more patients globally.”
